COVID-19 Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D04CLH
|
|||
| Drug Name |
PMID26048809-compound2
|
|||
| Synonyms |
PMID26048809-C2
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Middle East Respiratory Syndrome (MERS) | Preclinical | [1] | |
| Therapeutic Class |
Antiviral Agents
|
|||
| Structure |
 |
Download2D MOL |
||
| Target | Top | |||
|---|---|---|---|---|
| Target(s) | MERS-CoV RNA-directed RNA polymerase (RdRp) | Target Info | Inhibitor | [1] |
| Compound 2 displays selective antiviral activity (CC50 >3 EC50) towards MERS-CoV via inhibiting RNA-directed RNA polymerase. | ||||
| References | Top | |||
|---|---|---|---|---|
| 1 | Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.